In particular, since Src kinase activity is aberrantly upregulated in many glioblastoma and can trigger Caspase-8 phosphorylation in these contexts, cotreatment with Src kinase inhibitors, such as dasatinib, already in clinical trials, may represent a valuable approach to enhance Caspase-8 apoptotic activation in response to radio and chemotherapy as well as to TRAIL receptor stimulation. The gene discussed is CASP8; the disease is glioblastoma.